Alteogen lands $365m licensing deal
- Source
- The Korea Herald - Business
- Source link
- https://www.koreaherald.com/article/10831548
- Published
- 2026-08-05 11:21:08
- Discovered by ProcIntel
- 2026-08-05 04:56:25
- Category
- Procurement & Supply Chain News
- Geography
- South Korea
- Organisations
- —
- Review status
- Pending
- Record type
- REAL
Summary
Korean biotechnology firm Alteogen said Wednesday it has signed an exclusive licensing agreement worth up to $365 million with a global pharmaceutical company. Under the deal, the latter will develop and commercialize subcutaneous formulations of biologic drugs using Alteogen's proprietary recombinant human hyaluronidase platform ALT-B4. Also known by its generic name berahyaluronidase alfa, ALT-B4 is Alteogen's proprietary recombinant human hyaluronidase developed using the company's Hybrozyme
Procurement Relevance Gate
- geographic_exposure (weight 8) — matched on "1 linked geography"
Initial Signal Assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically-computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Not Assessed — this Signal did not pass the Procurement Relevance Gate, or is fictional/excluded test data.